JPRN-UMIN000054168
Not yet recruiting
未知
A nationwide retrospective study of malignant tumors arising from ovarian mature teratoma in Japan - JGOG3034
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Japanese Gynecologic Oncology Group
- Enrollment
- 200
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The individual or family member has clearly expressed a refusal to opt out. The researcher considers it inappropriate, citing difficulties in obtaining data.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-PTBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-ESBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatiopan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004362-34-NLBristol-Myers Squibb International Corporation1,231
Active, not recruiting
Phase 1
Study to evaluate long-term safety of nivolumab for subjects with cancer who will be provided nivolumab or have finished treatment and are now in or have completed follow up on another study of nivolumab or nivolumab combinatioEUCTR2018-004362-34-NOBristol-Myers Squibb International Corporation1,231
Withdrawn
Phase 2
Pan Tumor Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating NivolumabNL-OMON50106Bristol-Myers Squibb10